AZN Astrazeneca Plc

TIDMAZN

RNS Number : 7328Q

AstraZeneca PLC

01 December 2016

1 December 2016 15:00

Transparency Directive

Voting Rights and Capital

The following notification is made in accordance with the UK Financial Conduct Authority's Disclosure and Transparency Rule 5.6.1. On 30 November 2016 the issued share capital of AstraZeneca PLC with voting rights is 1,265,051,385 ordinary shares of US$0.25. No shares are held in Treasury. Therefore, the total number of voting rights in AstraZeneca PLC is 1,265,051,385.

The above figure for the total number of voting rights may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, AstraZeneca PLC under the UK Financial Conduct Authority's Disclosure and Transparency Rules.

About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three main therapy areas - Oncology, Cardiovascular & Metabolic Diseases and Respiratory. The Company also is selectively active in the areas of autoimmunity, neuroscience and infection. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information, please visit www.astrazeneca.com and follow us on Twitter @AstraZeneca.

 
 Media Enquiries 
 Neil Burrows           UK/Global                                 +44 203 749 5637 
 Vanessa Rhodes         UK/Global                                 +44 203 749 5736 
 Karen Birmingham       UK/Global                                 +44 203 749 5634 
 Rob Skelding           UK/Global                                 +44 203 749 5821 
 Jacob Lund             Sweden                                    +46 8 553 260 20 
 Michele Meixell        US                                        +1 302 885 2677 
 
 Investor Relations 
 Thomas Kudsk Larsen                                              +44 203 749 5712 
 Craig Marks            Finance, Fixed Income, M&A                +44 7881 615 764 
 Henry Wheeler          Oncology                                  +44 203 749 5797 
 Mitchell Chan          Oncology                                  +1 240 477 3771 
 Lindsey Trickett       Cardiovascular & Metabolic Diseases       +1 240 543 7970 
 Nick Stone             Respiratory                               +44 203 749 5716 
 Christer Gruvris       Autoimmunity, neuroscience & infection    +44 203 749 5711 
 US toll free                                                     +1 866 381 7277 
 

Adrian Kemp

Company Secretary, AstraZeneca PLC

-ENDS-

This information is provided by RNS

The company news service from the London Stock Exchange

END

TVRLLFISFALLIIR

(END) Dow Jones Newswires

December 01, 2016 10:00 ET (15:00 GMT)

Astrazeneca (LSE:AZN)
Historical Stock Chart
From Jan 2025 to Feb 2025

Astrazeneca (LSE:AZN)
Historical Stock Chart
From Feb 2024 to Feb 2025